HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
Why are ADCs consistently outperforming conventional chemotherapy?
Dr Huppert highlights ADC targeting technology and the value of diverse targets and payloads for improved efficacy and tolerability.
Play episode from 37:46
Transcript
